Pharma: Page 10
-
Stock via Getty Images
Read to lead: 6 books pharma execs swear by
From an epic, alternative reality fantasy to a ‘biography of cancer,’ these six reads have stuck with pharma execs as they navigate how to lead.
By Alexandra Pecci • Aug. 1, 2024 -
Spencer Platt / Staff via Getty Images
3 Big Pharma cancer drugs facing inflation penalties
The U.S. government will demand payment from Big Pharma to make up for dozens of drugs with prices that rose faster than the rate of inflation.
By Amy Baxter • July 31, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
Permission granted by Sanofi
7 years after launch, Sanofi’s Dupixent is set for a megablockbuster run
Dupixent hasn’t generated as much buzz as top-sellers like Keytruda or Ozempic, but the drug is boosting Sanofi’s earnings into the future.
By Michael Gibney • July 30, 2024 -
Permission granted by Biogen
Sage’s recent trial failure adds pressure to its two-drug Biogen collab
The mid-stage failure leaves the success of the expensive partnership hanging on a drug that’s already suffered its own setback.
By Amy Baxter • July 29, 2024 -
Stock via Getty Images
Citius’ first FDA decision date is approaching — and its CEO has millions on the line
Citius Pharmaceuticals CEO Leonard Mazur has personally invested $22.5 million into the company, which is fast approaching a potential turning point.
By Amy Baxter • July 26, 2024 -
Permission granted by Mubadala Capital
Q&AIn biotech’s new market normal, here’s what’s catching this investor’s eye
A VC investor shares how the market is recovering, which kinds of companies he’s hunting for and where he’d love to see more innovation.
By Meagan Parrish • July 25, 2024 -
Chris duMond via Getty Images
Where Kamala Harris stands on three key pharma issues
The presumptive Democratic nominee has a long history of taking on pharma over drug prices and supporting women’s healthcare access.
By Amy Baxter • July 24, 2024 -
Brian Tucker / BioPharma Dive
Private biotech M&A surges amid difficult IPO market
Private biotech company acquisitions are on their fastest pace in years, a trend some in the industry say is driven by the abundance of mature, but not yet public, drug startups.
By Gwendolyn Wu • July 23, 2024 -
Alex Wong / Staff via Getty Images
Q&ABird flu puts BARDA back in the spotlight
BARDA director Gary Disbrow explains the agency’s focus, how companies can get their “foot in the door” and why platforms are so important for preparedness.
By Alexandra Pecci • July 23, 2024 -
Stock via Getty Images
To overcome barriers, cell and gene therapies need outside support
With great potential in cell and gene therapies, there are still plenty of barriers to getting the breakthroughs to patients.
By Kelly Bilodeau • July 22, 2024 -
Stock via Getty Images
Kyverna follows oncology’s CAR-T cell playbook for an ultra-rare autoimmune disorder
The pharma company is tackling the “stiff person syndrome” that afflicts Celine Dion in a phase 2 trial for its lead CAR-T candidate.
By Amy Baxter • July 19, 2024 -
Justin Sullivan via Getty Images
Gilead’s CMO to depart next year
Merdad Parsey joined Gilead as its chief medical officer in 2019 and has helped lead the company’s expansion into oncology, with mixed success.
By Ned Pagliarulo • July 19, 2024 -
Permission granted by Gilead
Gilead eyes ‘ending the HIV epidemic’ via incremental progress
With a long elusive HIV cure ever on the horizon, Gilead’s latest long-acting PrEP study shows that every step counts.
By Michael Gibney • July 18, 2024 -
Permission granted by Amylyx
Q&AAmylyx’s CEOs on their ALS setback and quest to revamp the pipeline
Co-CEOs Josh Cohen and Justin Klee reflect on what they learned from Relyvrio’s failure and how they’re carrying those lessons forward with other drugs.
By Meagan Parrish • July 17, 2024 -
Getty Images via Getty Images
Has pharma emerged from the ‘age of uncertainty’?
An industry reeling from a precarious market is showing signs of stabilizing as the future becomes a little less cloudy, an Evaluate report suggests.
By Michael Gibney • July 16, 2024 -
Courtesy of BMS
BMS’ long-standing leukemia blockbuster stares down its first generic
Patent disputes in the U.S. and abroad have opened the door to new generics ready for launch as soon as September for BMS’ Sprycel.
By Amy Baxter • July 12, 2024 -
Rebecca Pifer/PharmaVoice
As feds crack down on PBMs for drug costs, Big Pharma could lose some of the heat
Drugmakers pointed the finger at PBMs for being the culprit behind rising drug prices in the U.S. for years — now, an ongoing FTC investigation has their back.
By Michael Gibney • July 11, 2024 -
Jeenah Moon via Getty Images
Pfizer research chief Dolsten to step down, with company at a crossroads
The company has begun searching for a successor to Dolsten, who oversaw more than 35 drug and vaccine approvals alongside notable setbacks during his time as Pfizer’s top scientist.
By Ben Fidler • July 10, 2024 -
Douglas Cliff via Getty Images
As the GLP-1 market booms, other healthcare companies are cashing in
With more Americans taking obesity medications, adjacent businesses are offering supportive services to offset side effects, collect data and foster new health benefits.
By Amy Baxter • July 10, 2024 -
Stock via Getty Images
Could pharma’s blockbuster immunotherapies work in dogs?
Vetigenics believes it’s found a way to make pricey antibody-based technologies more accessible for animals.
By Alexandra Pecci • July 9, 2024 -
Permission granted by Eli Lilly
FDA approval is just the beginning. Now Lilly’s Kisunla faces the tough Alzheimer’s market.
Recent history suggests an Alzheimer’s approval doesn’t necessarily translate to market triumph. Perhaps for Eli Lilly’s Kisunla, this time could be different.
By Michael Gibney • July 9, 2024 -
Getty Images via Getty Images
The FDA pushes concrete plans to further diversity in clinical trials
The long-awaited guidance offers a more detailed road map for pharma.
By Kelly Bilodeau • July 8, 2024 -
Permission granted by BeiGene
Q&AHow BeiGene is taking on established blockbusters with an expanding blood cancer arsenal
BeiGene’s Brukinsa is the first in a hematology franchise that the company hopes will rival top-sellers and introduce a new lineup of medicines for patients.
By Michael Gibney • July 2, 2024 -
Stock via Getty Images
The IRA will lower U.S. drug spending, CMS finds — but not for awhile
As the first 10 drugs undergo price negotiations with the U.S. government, the latest spending projections reveal soon-to-be-implemented price caps will have an impact by 2027.
By Amy Baxter • July 1, 2024 -
Stock via Getty Images
Up-and-comers look for an edge in the bustling ADC field
The next wave of targeted ADC therapies is on the horizon, and these three potential rising stars could help carry the field forward.
By Meagan Parrish • June 28, 2024
Previous
